Evidence map›Paper›PMID 41561148›Full record

ReviewFrontiers in network physiology2025

Evaluation of deep learning tools in medical diagnosis and treatment of cancer: research analysis of clinical and randomized clinical trials.

Rawad Hodeify

Abstract readReview
In one paragraph

Review in Frontiers in network physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Rawad HodeifyDepartment of Biotechnology, School of Arts and Sciences, American University of Ras Al Khaimah, Ras Al Khaimah, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial Intelligence and machine learning tools have brought a revolution in the healthcare sector. This has allowed healthcare providers, patients, and public to be at pole position -amidst the key consideration and barriers-to attain precision and personalized medicine. Deep Learning (DL) is a branch of machine learning and AI that has become transformative for healthcare and biomedicine, providing the ability to analyze large, complicated data, capture abstract patterns, and present fast and accurate predictions. DL models are based on complex neural networks that emulate biological neural networks. In this paper, our goal is to evaluate DL algorithms in clinical trials stratified per cancer type and present future perspectives on the most promising DL approaches. We systematically reviewed articles on deep learning in cancer diagnostics in studies published in the Pubmed database. The searched literature included two types of articles, clinical trials, and randomized controlled trials. The deep learning algorithms used in the targeted literature are reviewed, and then we evaluated the performance of the algorithms used in disease prediction and prognosis. We aim to highlight the promising DL approaches reported per cancer type. Finally, we present current limitations and potential recommendations in large-scale implementation of deep learning and AI in cancer care.

Indexed as

algorithmcancercancer diagnosisclassificationclinical trialsdeep learningneural networksprediction

Identifiers

PMID41561148
PMCPMC12812991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.